Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules.
Pseudomonas aeruginosa releases a spectrum of well-regulated virulence factors, controlled by intercellular communication (quorum sensing) and mediated through the production of small diffusible quorum-sensing signal molecules (QSSM). We hypothesize that QSSM may in fact serve a dual purpose, also allowing bacterial colonization via their intrinsic immune-modulatory capacity. One class of signal molecule, the N-acylhomoserine lactones, has pleiotropic effects on eukaryotic cells, particularly those involved in host immunity. In the present study, we have determined the comparative effects of two chemically distinct and endobronchially detectable QSSM, N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) and 2-heptyl-3-hydroxy-4 (1H)-quinolone or the Pseudomonas quinolone signal (PQS), on human leukocytes exposed to a series of stimuli designed to detect differential immunological activity in vitro. 3-Oxo-C12-HSL and PQS displayed differential effects on the release of interleukin-2 (IL-2) when human T cells were activated via the T-cell receptor and CD28 (a costimulatory molecule). 3-Oxo-C12-HSL inhibited cell proliferation and IL-2 release; PQS inhibited cell proliferation without affecting IL-2 release. Both molecules inhibited cell proliferation and the release of IL-2 following mitogen stimulation. Furthermore, in the presence of Escherichia coli lipopolysaccharide, 3-oxo-C12-HSL inhibited tumor necrosis factor alpha release from human monocytes, as reported previously (K. Tateda et al., Infect. Immun. 64:37-43, 1996), whereas PQS did not inhibit in this assay. These data highlight the presence of two differentially active immune modulatory QSSM from P. aeruginosa, which are detectable endobronchially and may be active at the host/pathogen interface during infection with P. aeruginosa, should the bronchial airway lymphoid tissues prove to be accessible to QSSM.
Hooi
Doreen S W
DS
School of Pharmacy, University of Nottingham, University Park, NG7 2RD, UK.
Bycroft
Barrie W
BW
Chhabra
Siri Ram
SR
Williams
Paul
P
Pritchard
David I
DI
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D003208:Concanavalin A / Q000494:pharmacology; D005786:Gene Expression Regulation; D006714:Homoserine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity*; D015363:Quinolones / Q000494:pharmacology*; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
C407944:2-heptyl-3-hydroxy-4-quinolone; D007376:Interleukin-2; D008070:Lipopolysaccharides; C109860:N-(3-oxododecanoyl)homoserine lactone; D015363:Quinolones; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; C088386:homoserine lactone; D006714:Homoserine; D015107:4-Butyrolactone